4.7 Article

A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts

期刊

BIOLOGICAL PSYCHIATRY
卷 90, 期 9, 页码 611-620

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2021.04.018

关键词

-

资金

  1. National Health and Medical Research Council [1173790, 1078901, 108788, 1113400]
  2. Australian Research Council [FL180100072]
  3. National Institute of Mental Health [U01 MH109528, R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289, U01 MH46318, U01 MH79469, U01 MH79470]
  4. German Research Foundation [FOR2107 DA1151/5-1, DA1151/5-2, SFB-TRR58]
  5. Interdisciplinary Center for Clinical Research of the Faculty of Medicine of Munster [Dan3/012/17]
  6. National Institutes of Health [P50 CA093459, P50 CA097007, R01 ES011740, R01 CA133996]
  7. Netherlands Scientific Organization [480-05-003]
  8. Dutch Brain Foundation
  9. VU University Amsterdam
  10. National Health and Medical Research Council of Australia [1173790] Funding Source: NHMRC

向作者/读者索取更多资源

The study evaluated the genetic risk for schizophrenia and major depressive disorder, revealing that PGS methods with more formal genetic architecture modeling have better prediction statistics. MegaPRS, LDpred2, and SBayesR are recommended for applications to these disorders based on their superior performance compared to other methods.
BACKGROUND: Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease, are calculated as a weighted count of risk alleles identified in genome-wide association studies. PGS methods differ in which DNA variants are included and the weights assigned to them; some require an independent tuning sample to help inform these choices. PGSs are evaluated in independent target cohorts with known disease status. Variability between target cohorts is observed in applications to real data sets, which could reflect a number of factors, e.g., phenotype definition or technical factors. METHODS: The Psychiatric Genomics Consortium Working Groups for schizophrenia and major depressive disorder bring together many independently collected case-control cohorts. We used these resources (31,328 schizophrenia cases, 41,191 controls; 248,750 major depressive disorder cases, 563,184 controls) in repeated application of leaveone-cohort-out meta-analyses, each used to calculate and evaluate PGS in the left-out (target) cohort. Ten PGS methods (the baseline PC+T method and 9 methods that model genetic architecture more formally: SBLUP, LDpred2-Inf, LDpred-funct, LDpred2, Lassosum, PRS-CS, PRS-CS-auto, SBayesR, MegaPRS) were compared. RESULTS: Compared with PC+T, the other 9 methods gave higher prediction statistics, MegaPRS, LDPred2, and SBayesR significantly so, explaining up to 9.2% variance in liability for schizophrenia across 30 target cohorts, an increase of 44%. For major depressive disorder across 26 target cohorts, these statistics were 3.5% and 59%, respectively. CONCLUSIONS: Although the methods that more formally model genetic architecture have similar performance, MegaPRS, LDpred2, and SBayesR rank highest in most comparisons and are recommended in applications to

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据